Seminars in Oncology

Papers
(The TQCC of Seminars in Oncology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
TOC71
Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis56
Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review25
Integrated analysis of scRNA-seq and bulk RNA-seq data identifies BHLHE40 as a key gene in pancreatic cancer progression and gemcitabine resistance24
Editorial Board22
Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics20
Role of neoadjuvant pembrolizumab in advanced melanoma20
Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans14
Global distribution of prophylactic total gastrectomy in E-cadherin (CDH1) mutations14
Military exposures and lung cancer in United States Veterans14
Adenocarcinoma on retrorectal cystic hamartoma: An illustrative image for a very rare diagnosis13
Editorial Board13
Masthead12
The Impact of HIV on Non-AIDS defining gastrointestinal malignancies: A review12
Assessment of PSA responses and changes in the rate of tumor growth -rate with immune checkpoint inhibitors in US Veterans with prostate cancer11
Liquid Biopsy, the hype vs. hope in molecular and clinical oncology11
Masthead10
The interest of therapeutic and pharmacological drug monitoring of methotrexate: A systematic review10
Masthead9
The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S.9
Impact of the COVID-19 Pandemic on the Wellbeing of International Oncology and Hematology Fellows at the Princess Margaret Cancer Center (PMCC)9
Editorial Board8
Immune checkpoint inhibitors in patients with chronic kidney disease: Assessing their ability to cause acute kidney injury and informing their proper use8
Screening Adherence for Second Primary Malignancies in Breast Cancer Survivors: Behaviors, Facilitators, and Barriers to Enhance Quality Care8
Acute liver failure secondary to malignant infiltration: A single center experience8
Biomarkers and the microbiome in the detection and treatment of early-stage non-small cell lung cancer8
Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran8
The challenges of selecting cancer medicines for the WHO Essential Medicines List with the elephant in the room: A path forward7
outside front cover6
Surgery for early-stage lung cancer with video-assisted thoracoscopic surgery versus open thoracotomy: A narrative review6
Barriers and facilitators to lung cancer screening and follow-up6
Editorial Board6
Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing—The experience of a large oncology center in t6
Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects6
Current and prospective antibody-based therapies in multiple myeloma6
Masthead6
A narrative review of the principal glucocorticoids employed in cancer6
Treating advanced lung cancer in older Veterans with comorbid conditions and frailty5
High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy5
Landmark trials in the medical oncology management of metastatic breast cancer5
Colorectal cancer in Ethiopia: Epidemiological trends, diagnostic and laboratory capacities, and challenges5
outside front cover5
Managing multiple myeloma in a resource-limited region: Diagnosis and treatment in Armenia5
Radiation recall dermatitis: A review of the literature5
Daratumumab: A review of current indications and future directions4
Table of Contents4
Outcomes with panobinostat in heavily pretreated multiple myeloma patients4
PARP inhibitors in ovarian cancer4
Masthead4
outside front cover4
The impact of the COVID-19 pandemic on tertiary care cancer center: Analyzing administrative data4
CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety4
Cancer genetic mutation prevalence in sub-Saharan Africa: A review of existing data4
Comorbidity and life expectancy in shared decision making for lung cancer screening4
0.036968946456909